KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBT Margin (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of EBT Margin data on record, last reported at 41.72% in Q4 2025.

  • For Q4 2025, EBT Margin rose 270.0% year-over-year to 41.72%; the TTM value through Dec 2025 reached 38.69%, up 3643.0%, while the annual FY2025 figure was 38.69%, 3643.0% up from the prior year.
  • EBT Margin reached 41.72% in Q4 2025 per VRTX's latest filing, down from 42.22% in the prior quarter.
  • Across five years, EBT Margin topped out at 54.57% in Q3 2021 and bottomed at 128.18% in Q2 2024.
  • Average EBT Margin over 5 years is 33.22%, with a median of 44.84% recorded in 2022.
  • Peak YoY movement for EBT Margin: tumbled -17477bps in 2024, then surged 17146bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 42.02% in 2021, then increased by 11bps to 46.76% in 2022, then dropped by -3bps to 45.58% in 2023, then decreased by -14bps to 39.03% in 2024, then grew by 7bps to 41.72% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 41.72% in Q4 2025, 42.22% in Q3 2025, and 43.28% in Q2 2025.